Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Voting Common Shares, no par value
-
Shares outstanding
-
51.9M
-
Number of holders
-
17
-
Total 13F shares, excl. options
-
2.92M
-
Shares change
-
+2.12M
-
Total reported value, excl. options
-
$8.23M
-
Value change
-
+$5.98M
-
Number of buys
-
12
-
Number of sells
-
-2
-
Price
-
$2.80
Significant Holders of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) as of Q1 2020
18 filings reported holding DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value as of Q1 2020.
DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) has 17 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.92M shares
of 51.9M outstanding shares and own 5.63% of the company stock.
Largest 10 shareholders include Stonepine Capital Management, LLC (825K shares), Nantahala Capital Management, LLC (750K shares), Granite Point Capital Management, L.P. (477K shares), Manatuck Hill Partners, LLC (351K shares), VANGUARD GROUP INC (242K shares), Worth Venture Partners, LLC (106K shares), GEODE CAPITAL MANAGEMENT, LLC (57.5K shares), BlackRock Inc. (38.4K shares), RENAISSANCE TECHNOLOGIES LLC (25.8K shares), and NORTHERN TRUST CORP (12.5K shares).
This table shows the top 17 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.